Minimal clinically important change in the Toronto Western Spasmodic Torticollis Rating Scale

被引:22
作者
Espay, Alberto J. [1 ]
Trosch, Richard [2 ]
Suarez, Gustavo [3 ]
Johnson, Jonathan [4 ]
Marchese, Dominic [3 ]
Comella, Cynthia [5 ]
机构
[1] Univ Cincinnati, Dept Neurol, James J & Joan A Gardner Ctr Parkinsons Dis & Mov, Cincinnati, OH USA
[2] Oakland Univ, William Beaumont Sch Med, Farmington Hills, CT USA
[3] Ipsen Biopharmaceut, Basking Ridge, NJ USA
[4] OptumInsight, Eden Prairie, MN USA
[5] Rush Univ, Med Ctr, Dept Neurol, Chicago, IL 60612 USA
关键词
Cervical dystonia; Toronto western spasmodic torticollis rating scale; Minimal clinically important change; Botulinum toxin abobotulinumtoxinA; CERVICAL DYSTONIA; PARKINSONS-DISEASE; EFFICACY; SAFETY;
D O I
10.1016/j.parkreldis.2018.03.002
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: To characterize the minimal clinically important change (MCIC) after treatment in cervical dystonia patients using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). Methods: Changes in the TWSTRS from an observational study of abobotulinumtoxinA in the routine management of cervical dystonia (NCT01314365) were analyzed using the Patient Global Impression of Change (PGIC) as anchor. Results: For the overall population (N = 304, baseline TWSTRS-Total score 43.4 +/- 19.4), the MCIC for the TWSTRS Total score was -11.9 (95%CI: -13.9, -10.0; p < 0.0001). However, thresholds ranged from -3.2 to -18.0 dependent on baseline severity. TWSTRS-Total scores improved linearly by 3 points for every one-point PGIC increase. There was similar linearity between the graded PGIC categories and TWSTRS subscale scores (severity, disability, and pain). Conclusions: A 3-point change is the minimal clinically important change after treatment using TWSTRS as endpoint with higher cutoffs for greater baseline disease severity. For an average trial population (TWSTRS-total: 40-45), a 12-point decrease is clinically meaningful. (C) 2018 Elsevier Ltd. All rights reserved.
引用
收藏
页码:94 / 97
页数:4
相关论文
共 12 条
  • [1] Teaching tape for the motor section of the Toronto western spasmodic torticollis scale
    Comella, CL
    Stebbins, GT
    Goetz, CG
    Chmura, TA
    Bressman, SB
    Lang, AE
    [J]. MOVEMENT DISORDERS, 1997, 12 (04) : 570 - 575
  • [2] Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release
    Hauser, Robert A.
    Gordon, Mark Forrest
    Mizuno, Yoshikuni
    Poewe, Werner
    Barone, Paolo
    Schapira, Anthony H.
    Rascol, Olivier
    Debieuvre, Catherine
    Fraessdorf, Andmandy
    [J]. PARKINSONS DISEASE, 2014, 2014
  • [3] Determination of Minimal Clinically Important Change in Early and Advanced Parkinson's Disease
    Hauser, Robert A.
    Auinger, Peggy
    [J]. MOVEMENT DISORDERS, 2011, 26 (05) : 813 - 818
  • [4] Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapy
    Jost, Wolfgang H.
    Hefter, Harald
    Stenner, Andrea
    Reichel, Gerhard
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2013, 120 (03) : 487 - 496
  • [5] Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study
    Misra, Vijay P.
    Ehler, Edvard
    Zakine, Benjamin
    Maisonobe, Pascal
    Simonetta-Moreau, Marion
    [J]. BMJ OPEN, 2012, 2 (03):
  • [6] Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial
    Poewe, Werner
    Burbaud, Pierre
    Castelnovo, Giovanni
    Jost, Wolfgang H.
    Ceballos-Baumann, Andres O.
    Banach, Marta
    Potulska-Chromik, Anna
    Ferreira, Joaquim J.
    Bihari, Katalin
    Ehler, Edvard
    Bares, Martin
    Dzyak, Lyudmyla A.
    Belova, Anna N.
    Pham, Emmanuel
    Liu, Wenzhong Jerry
    Picaut, Philippe
    [J]. MOVEMENT DISORDERS, 2016, 31 (11) : 1649 - 1657
  • [7] Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes
    Revicki, Dennis
    Hays, Ron D.
    Cella, David
    Sloan, Jeff
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2008, 61 (02) : 102 - 109
  • [8] Minimal clinically important change on the Unified Parkinson's Disease Rating Scale
    Schrag, Anette
    Sampaio, Cristina
    Counsell, Nicholas
    Poewe, Werner
    [J]. MOVEMENT DISORDERS, 2006, 21 (08) : 1200 - 1207
  • [9] The Clinically Important Difference on the Unified Parkinson's Disease Rating Scale
    Shulman, Lisa M.
    Gruber-Baldini, Ann L.
    Anderson, Karen E.
    Fishman, Paul S.
    Reich, Stephen G.
    Weiner, William J.
    [J]. ARCHIVES OF NEUROLOGY, 2010, 67 (01) : 64 - 70
  • [10] Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry
    Trosch, Richard M.
    Espay, Alberto J.
    Truong, Daniel
    Gil, Ramon
    Singer, Carlos
    LeWitt, Peter A.
    Lew, Mark F.
    Tagliati, Michele
    Adler, Charles H.
    Chen, Jack J.
    Marchese, Dominic
    Comella, Cynthia L.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 376 : 84 - 90